EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
Dubsky, P., Filipits, M., Jakesz, R., Rudas, M., Singer, C.F., Greil, R., Dietze, O., Luisser, I., Klug, E., Sedivy, R., Bachner, M., Mayr, D., Schmidt, M., Gehrmann, M.C., Petry, C., Weber, K.E., Kronenwett, R., Brase, J.C., Gnant, M.
Published in Annals of oncology (01.03.2013)
Published in Annals of oncology (01.03.2013)
Get full text
Journal Article
898 Circulating MicroRNAs Associated With Early Relapse in Early-stage NSCLC
Kuner, R, Kaduthanam, S, Gade, S, Brase, J.C, Johannes, M, Sultmann, H, Muley, T, Meister, M, Herth, F.J, Dienemann, H
Published in European journal of cancer (1990) (01.07.2012)
Published in European journal of cancer (1990) (01.07.2012)
Get full text
Journal Article
1395TiP A randomized phase III trial evaluating oral BAY 2927088, compared with standard of care, as first-line treatment of locally advanced or metastatic NSCLC harboring HER2-activating mutations (SOHO-02)
Passaro, A., Brase, J.C., Xu, J., Mongay Soler, L., Goto, K.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
LBA4 CANOPY-N: A phase II study of canakinumab (CAN) or pembrolizumab (PEM), alone or in combination, as neoadjuvant therapy in patients (pts) with resectable stage Ib–IIIa non-small cell lung cancer (NSCLC)
Mok, T.S.K., Pujol, J-L., Tsuboi, M., Lee, J., Kim, E., Leonov, O., Zhang, J., Duan, J., Lobetti-Bodoni, C., Brase, J.C., Savchenko, A., Garrido Lopez, P.
Published in Annals of oncology (01.11.2022)
Published in Annals of oncology (01.11.2022)
Get full text
Journal Article
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade
Nuciforo, P., Pascual, T., Cortés, J., Llombart-Cussac, A., Fasani, R., Paré, L., Oliveira, M., Galvan, P., Martínez, N., Bermejo, B., Vidal, M., Pernas, S., López, R., Muñoz, M., Garau, I., Manso, L., Alarcón, J., Martínez, E., Rodrik-Outmezguine, V., Brase, J.C., Villagrasa, P., Prat, A., Holgado, E.
Published in Annals of oncology (01.01.2018)
Published in Annals of oncology (01.01.2018)
Get full text
Journal Article
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial
Kulke, M.H., Ruszniewski, P., Van Cutsem, E., Lombard-Bohas, C., Valle, J.W., De Herder, W.W., Pavel, M., Degtyarev, E., Brase, J.C., Bubuteishvili-Pacaud, L., Voi, M., Salazar, R., Borbath, I., Fazio, N., Smith, D., Capdevila, J., Riechelmann, R.P., Yao, J.C.
Published in Annals of oncology (01.06.2017)
Published in Annals of oncology (01.06.2017)
Get full text
Journal Article
P2.05-13 Canakinumab with Standard of Care for Patients with Advanced NSCLC: T-cell Infiltration Analysis in CANOPY-1
Tan, D.S., Felip, E., de Castro Junior, G., Solomon, B.J., Greystoke, A., Cho, B.C., Cobo, M., Kim, T.M., Ganguly, S., Wu, J., Demanse, D., Butler, A.A., Brase, J.C., Bossen, C., Johnson, B.E.
Published in Journal of thoracic oncology (01.11.2023)
Published in Journal of thoracic oncology (01.11.2023)
Get full text
Journal Article
LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial
Nathan, P., Dummer, R., Long, G.V., Ascierto, P.A., Tawbi, H.A., Robert, C., Rutkowski, P., Leonov, O., Dutriaux, C., Mandala', M., Lorigan, P., Ferrucci, P.F., Flaherty, K.T., Brase, J.C., Green, S., Haas, T., Masood, A., Gasal, E., Ribas, A., Schadendorf, D.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
PAM50 intrinsic subtype in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial
Prat, A., Brase, J.C., Cheng, Y., Nuciforo, P., Paré, L., Pascual, T., Martinez, D., Galvan, P., Vidal, M., Adamo, B., Hortobagyi, G., Baselga, J., Ciruelos, E.
Published in European journal of cancer (1990) (01.04.2018)
Published in European journal of cancer (1990) (01.04.2018)
Get full text
Journal Article
404 (PB-037) - PAM50 intrinsic subtype in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial
Prat, A., Brase, J.C., Cheng, Y., Nuciforo, P., Paré, L., Pascual, T., Martinez, D., Galvan, P., Vidal, M., Adamo, B., Hortobagyi, G., Baselga, J., Ciruelos, E.
Published in European journal of cancer (1990) (01.04.2018)
Published in European journal of cancer (1990) (01.04.2018)
Get full text
Journal Article
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial
Kulke, M.H., Ruszniewski, P., Van Cutsem, E., Lombard-Bohas, C., Valle, J.W., De Herder, W.W., Pavel, M., Degtyarev, E., Brase, J.C., Bubuteishvili-Pacaud, L., Voi, M., Salazar, R., Borbath, I., Fazio, N., Smith, D., Capdevila, J., Riechelmann, R.P., Yao, J.C.
Published in Annals of oncology (01.11.2019)
Published in Annals of oncology (01.11.2019)
Get full text
Journal Article
Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600–mutant stage III melanoma
Long, G.V., Hauschild, A., Santinami, M., Atkinson, V.G., Mandala, M., Chiarion-Sileni, V., Larkin, J., Robert, C., Schadendorf, D., Dasgupta, K., Shilkrut, M., Garrett, J., Brase, J.C., Kefford, R., Kirkwood, J.M., Dummer, R.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
PAM50MET: A prognostic model based on PAM50 and clinical variables in metastatic hormone receptor (HR)-positive/HER2 negative breast cancer
Prat, A., Tsai, Y.-H., Pascual, T., Paré, L., Vidal, M., Adamo, B., Brase, J.C., Johnston, S.R.D., Ciruelos, E.M., Parker, J.S.
Published in Annals of oncology (01.05.2019)
Published in Annals of oncology (01.05.2019)
Get full text
Journal Article
48P Comparison of an Rna-Based Multigene Test Between Core Biopsies and Corresponding Surgical Breast Cancer Sections
Brase, J.C., Müller, B.M., Haufe, F., Weber, K.E., Budzies, J., Petry, C., Prinzler, J., Kronenwett, R., Dietel, M., Denkert, C.
Published in Annals of oncology (01.05.2012)
Published in Annals of oncology (01.05.2012)
Get full text
Journal Article